.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
GPR84 receptor antagonists are now a focal point in drug discovery for chronic inflammation and fibrotic tissue remodeling. GPR84 is a metabolite-sensing Class A GPCR primarily expressed on myeloid immune cells. Its activation by medium-chain fatty acids triggers a pro-inflammatory cascade. Consequently, inhibiting this pathway offers a novel approach to treating conditions like inflammatory bowel disease and idiopathic pulmonary fibrosis.
Recent patent filings from 2020 to 2026 reveal an expansion in the chemical diversity of GPR84 modulators. Researchers are developing more selective and potent molecules. While candidates like GLPG1205 paved the way, newer molecules such as BGT-004 are now under scrutiny. Furthermore, these advancements demonstrate a concerted effort to optimize oral bioavailability for better patient compliance. However, development remains volatile. For example, the candidate BAY-3178275 recently faced discontinuation in Phase 1 trials for diabetic neuropathic pain. This setback highlights the biological complexities inherent in targeting this receptor.
Clinical translation of GPR84 receptor antagonists still faces significant hurdles. Specifically, uncertainty regarding the receptor's primary endogenous ligand persists. Furthermore, its role in various tissue microenvironments remains complex and not fully understood. Nevertheless, its inducible nature in disease states makes it a highly specific inflammation sensor. Consequently, future progress depends on identifying patient endotypes who will benefit most from GPR84 modulation. Deeper mechanistic insights are therefore essential to move these patent-stage molecules into clinical practice.
Researchers are investigating these antagonists for inflammatory and fibrotic disorders. Key interests include ulcerative colitis, non-alcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis.
GPR84 acts as an amplifier of the innate immune response. When activated by fatty acids, it promotes the chemotaxis of neutrophils and macrophages. This process leads to sustained pro-inflammatory signaling in damaged tissues.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Recent patent reviews show expanding chemical diversity in GPR84 receptor antagonists for treating inflammatory and fibrotic diseases. While candidates like BGT-004 show promise, clinical challenges like the discontinuation of BAY-3178275 highlight the need for deeper mechanistic understanding.
3 months ago
Depemokimab offers twice-yearly dosing for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, significantly cutting exacerbations and hospital admissions.
2 days back
A novel copper metal-organic framework hydrogel remodels the uterine microenvironment to stimulate robust endometrial regeneration, reduce intrauterine fibrosis, and restore reproductive fertility, offering a groundbreaking strategy for managing refractory endometrial damage and Asherman syndrome.
3 days back
New research reveals that non-ablative radiotherapy suppresses ventricular tachycardia by increasing conduction velocity via NaV1.5 upregulation and action potential prolongation. However, sustained sodium current elevation and depressed calcium handling highlight the need for careful clinical translation.
5 days back
A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 days back
A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 days back
